Senator Chuck Grassley, chairman of the Senate Judiciary Committee, opened an executive business meeting on March 19 to address several legislative items and nominations, including the Combating Illicit Xylazine Act. The committee also considered five nominations for key federal law enforcement positions and two bills focused on public safety.
The work of the Senate Judiciary Committee has broad implications for constitutional protections and public safety across the country, according to the official website. The committee reviews legislation, oversees federal law enforcement agencies, and evaluates judicial nominations as part of its mission to uphold the Constitution.
During his opening statement, Grassley said that bipartisan cooperation is essential in combating fraud and illegal drugs. He highlighted Colin McDonald’s nomination to lead the Justice Department’s National Fraud Enforcement Division, saying, “Mr. McDonald is a career public servant, and an expert in fraud prosecutions. He’s highly regarded because he’s prosecuted hard cases and done it well.” Grassley encouraged colleagues to support McDonald’s nomination.
A major focus of the meeting was S. 545, the Combating Illicit Xylazine Act. Grassley explained that xylazine is an animal tranquilizer not approved for human use but increasingly found mixed with fentanyl and other narcotics on the street. “Our bill will classify this highly toxic drug as Schedule III under the Controlled Substances Act, while protecting its legitimate use by veterinarians, farmers and ranchers,” he said. The bill has bipartisan support from both Democratic and Republican senators.
Grassley cited data showing a sharp rise in deaths involving xylazine across multiple states between 2020 and 2024. He shared personal stories from families affected by xylazine-related overdoses: “Mrs. Shannon Miller from Ohio lost her daughter two years ago... Mrs. Deborah Dinnocenzo is here today from Garfield, New Jersey... Mrs. Denise Prince traveled here today to honor her son, Joey.” Letters from family members were entered into the record alongside endorsements from federal agencies such as the Department of Health and Human Services and Drug Enforcement Administration.
The committee is led by a chair who oversees meetings attended by senators from both major political parties according to its official website. It serves as a standing committee of the U.S. Senate with authority over judicial matters nationwide based in Washington, D.C., influencing civil rights through oversight responsibilities.
As debate continues over how best to address emerging drug threats like xylazine while balancing legitimate uses in agriculture, Grassley concluded by thanking those who shared their experiences: “I can’t tell every story this morning, but I want to let everyone who shared their painful story with us to know this: we hear you.”
The outcome of these deliberations may shape future legislative efforts aimed at reducing drug-related harm while maintaining necessary legal protections.
